Pascal Soriot, who runs drugs giant AstraZeneca, has slipped to third place in our annual survey, after being replaced by the ...

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

How could Trump's demands that drugmakers lower U.S. prices or face penalties impact pharma and biotech stocks? Seeking Alpha ...

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and ...

So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific research and seems determined to scrap the research grants of Ivy League ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

As the gubernatorial election in Virginia heats up News 5 caught up with republican nominee Winsome Earle-Sears.

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

President Donald Trump notched his 200th day back in office Thursday, with the administration celebrating a lengthy list of wins across its latest chapter of actions and policies unfolding at a ...